Ewing’s Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major ewing’s sarcoma markets reached a value of US$ 47.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 74.5 Million by 2034, exhibiting a growth rate (CAGR) of 4.1% during 2024-2034.
The Ewing’s sarcoma market has been comprehensively analyzed in IMARC's new report titled "Ewing’s Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ewing's sarcoma is a rare type of oncological disease that affects primitive nerve tissue of bones or soft tissues surrounding the bones. It most commonly occurs in the long bones of the arms and legs but can also develop in the soft tissues of the limbs, chest, or abdomen. Individuals suffering from this condition may experience pain, tenderness or swelling near the affected area, bone pain, limping, extreme tiredness, fever with no known cause, unexplained weight loss, etc. The other infrequent symptoms include palpable soft-tissue mass, paralysis, loss of bladder control, and bone fractures. The diagnosis of Ewing's sarcoma is mainly made by reviewing the patient's underlying indications, medical history, and physical examination. Numerous other studies, like magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, etc., are also utilized to look for signs of bone damage. The healthcare provider may further perform a biopsy, which involves the removal of tiny samples of the affected region to examine it under a microscope and validate a diagnosis.
The increasing cases of genetic abnormalities that lead to the disruption of normal tissues and the formation of unhealthy cells throughout the body are primarily driving the Ewing's sarcoma market. In addition to this, the widespread adoption of radical chemotherapy, which aims at complete irradiation of tumors, is also bolstering the market growth. Furthermore, the escalating demand for antisense oligodeoxynucleotide therapy to treat locally advanced disease conditions by down-regulating the expression of the oncogenic cellular RNA associated with the development of Ewing's sarcoma is acting as another significant growth-inducing factor. Additionally, the inflating utilization of proton beam radiation technique, which delivers an effective dose and controls damage to healthy tissues surrounding the cancerous cells, is further creating a positive outlook for the market. Apart from this, the emerging popularity of autologous stem cell transplantation as a viable treatment option owing to reduced metastasis and improved disease-free survival of patients, is expected to drive the Ewing's sarcoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Ewing’s sarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Ewing’s sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Ewing’s sarcoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Ewing’s sarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Ewing’s sarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Ewing’s sarcoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Ewing’s sarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Ewing’s sarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Ewing’s sarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Ewing’s sarcoma across the seven major markets?
What is the size of the Ewing’s sarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Ewing’s sarcoma?
What will be the growth rate of patients across the seven major markets?
Ewing’s Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Ewing’s sarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Ewing’s sarcoma market?
What are the key regulatory events related to the Ewing’s sarcoma market?
What is the structure of clinical trial landscape by status related to the Ewing’s sarcoma market?
What is the structure of clinical trial landscape by phase related to the Ewing’s sarcoma market?
What is the structure of clinical trial landscape by route of administration related to the Ewing’s sarcoma market?
The Ewing’s sarcoma market has been comprehensively analyzed in IMARC's new report titled "Ewing’s Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ewing's sarcoma is a rare type of oncological disease that affects primitive nerve tissue of bones or soft tissues surrounding the bones. It most commonly occurs in the long bones of the arms and legs but can also develop in the soft tissues of the limbs, chest, or abdomen. Individuals suffering from this condition may experience pain, tenderness or swelling near the affected area, bone pain, limping, extreme tiredness, fever with no known cause, unexplained weight loss, etc. The other infrequent symptoms include palpable soft-tissue mass, paralysis, loss of bladder control, and bone fractures. The diagnosis of Ewing's sarcoma is mainly made by reviewing the patient's underlying indications, medical history, and physical examination. Numerous other studies, like magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, etc., are also utilized to look for signs of bone damage. The healthcare provider may further perform a biopsy, which involves the removal of tiny samples of the affected region to examine it under a microscope and validate a diagnosis.
The increasing cases of genetic abnormalities that lead to the disruption of normal tissues and the formation of unhealthy cells throughout the body are primarily driving the Ewing's sarcoma market. In addition to this, the widespread adoption of radical chemotherapy, which aims at complete irradiation of tumors, is also bolstering the market growth. Furthermore, the escalating demand for antisense oligodeoxynucleotide therapy to treat locally advanced disease conditions by down-regulating the expression of the oncogenic cellular RNA associated with the development of Ewing's sarcoma is acting as another significant growth-inducing factor. Additionally, the inflating utilization of proton beam radiation technique, which delivers an effective dose and controls damage to healthy tissues surrounding the cancerous cells, is further creating a positive outlook for the market. Apart from this, the emerging popularity of autologous stem cell transplantation as a viable treatment option owing to reduced metastasis and improved disease-free survival of patients, is expected to drive the Ewing's sarcoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Ewing’s sarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Ewing’s sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Ewing’s sarcoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Ewing’s sarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Ewing’s sarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Ewing’s sarcoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Ewing’s sarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Ewing’s sarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Ewing’s sarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Ewing’s sarcoma across the seven major markets?
What is the size of the Ewing’s sarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Ewing’s sarcoma?
What will be the growth rate of patients across the seven major markets?
Ewing’s Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Ewing’s sarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Ewing’s sarcoma market?
What are the key regulatory events related to the Ewing’s sarcoma market?
What is the structure of clinical trial landscape by status related to the Ewing’s sarcoma market?
What is the structure of clinical trial landscape by phase related to the Ewing’s sarcoma market?
What is the structure of clinical trial landscape by route of administration related to the Ewing’s sarcoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EWING’S SARCOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EWING’S SARCOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EWING’S SARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 EWING’S SARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EWING’S SARCOMA - UNMET NEEDS
10 EWING’S SARCOMA - KEY ENDPOINTS OF TREATMENT
11 EWING’S SARCOMA - MARKETED PRODUCTS
11.1 List of Ewing’s Sarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 EWING’S SARCOMA - PIPELINE DRUGS
12.1 List of Ewing’s Sarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Lurbinectedin - PharmaMar
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Vigil - Gradalis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Seclidemstat - Salarius Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Eribulin mesylate - Eisai Co Ltd
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. EWING’S SARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EWING’S SARCOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EWING’S SARCOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ewing’s Sarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ewing’s Sarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ewing’s Sarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ewing’s Sarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ewing’s Sarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ewing’s Sarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ewing’s Sarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ewing’s Sarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ewing’s Sarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ewing’s Sarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ewing’s Sarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ewing’s Sarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ewing’s Sarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ewing’s Sarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ewing’s Sarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ewing’s Sarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ewing’s Sarcoma - Access and Reimbursement Overview
16 EWING’S SARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EWING’S SARCOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EWING’S SARCOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EWING’S SARCOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EWING’S SARCOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EWING’S SARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 EWING’S SARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EWING’S SARCOMA - UNMET NEEDS
10 EWING’S SARCOMA - KEY ENDPOINTS OF TREATMENT
11 EWING’S SARCOMA - MARKETED PRODUCTS
11.1 List of Ewing’s Sarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 EWING’S SARCOMA - PIPELINE DRUGS
12.1 List of Ewing’s Sarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Lurbinectedin - PharmaMar
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Vigil - Gradalis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Seclidemstat - Salarius Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Eribulin mesylate - Eisai Co Ltd
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. EWING’S SARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EWING’S SARCOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EWING’S SARCOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ewing’s Sarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ewing’s Sarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ewing’s Sarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ewing’s Sarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ewing’s Sarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ewing’s Sarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ewing’s Sarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ewing’s Sarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ewing’s Sarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ewing’s Sarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ewing’s Sarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ewing’s Sarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ewing’s Sarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ewing’s Sarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ewing’s Sarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ewing’s Sarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ewing’s Sarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ewing’s Sarcoma - Access and Reimbursement Overview
16 EWING’S SARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EWING’S SARCOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EWING’S SARCOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
